Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: Possible relevance to the effects of mGlu5R blockade in Parkinson's disease

Maria Rosaria Domenici, Rosa Luisa Potenza, Alberto Martire, Roberto Coccurello, Antonella Pèzzola, Rosaria Reggio, Maria Teresa Tebano, Patrizia Popoli

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

This study was designed to test whether chronic treatment with the metabotropic glutamate receptor 5 (mGlu5R) antagonist MPEP showed antiparkinsonian effects in rats unilaterally lesioned with 6-hydroxydopamine (6-OHDA) (a "classic" model of Parkinson's disease, PD), and to evaluate whether chronic MPEP influenced the functional properties and/or the expression of striatal mGlu5Rs. Wistar rats were lesioned with 6-OHDA and then treated with MPEP (3 mg/kg/day, i.p.) or its vehicle over 2 weeks. Chronic MPEP did not induce measurable antiparkinsonian effects, since no differences were found between MPEP- and vehicle-treated animals in the pattern of L-DOPA-induced contralateral rotations. In corticostriatal slices taken from animals chronically treated with MPEP, the functional effects of the mGlu5R agonist CHPG were significantly reduced in the lesioned vs. the intact side, while no changes were found in slices taken from vehicle-treated rats. The binding of [3H]MPEP to striatal membranes showed that neither the maximal number of binding sites (Bmax) nor the dissociation constant (Kd) were changed by the lesion and/or by chronic MPEP. While chronic MPEP did not potentiate L-DOPA-induced turning in a classical model of PD, its ability to reduce mGlu5R-associated signal could help to explain the neuroprotective/ antiparkinsonian effects observed in other models of PD.

Original languageEnglish
Pages (from-to)646-654
Number of pages9
JournalJournal of Neuroscience Research
Volume80
Issue number5
DOIs
Publication statusPublished - Jun 1 2005

Fingerprint

Antiparkinson Agents
Oxidopamine
Parkinson Disease
Corpus Striatum
Metabotropic Glutamate 5 Receptor
Neuroprotective Agents
Wistar Rats
Binding Sites
Membranes

Keywords

  • Binding
  • Electrophysiology
  • L-DOPA
  • mGlu5 receptors
  • Parkinson's disease
  • Striatum

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats : Possible relevance to the effects of mGlu5R blockade in Parkinson's disease. / Domenici, Maria Rosaria; Potenza, Rosa Luisa; Martire, Alberto; Coccurello, Roberto; Pèzzola, Antonella; Reggio, Rosaria; Tebano, Maria Teresa; Popoli, Patrizia.

In: Journal of Neuroscience Research, Vol. 80, No. 5, 01.06.2005, p. 646-654.

Research output: Contribution to journalArticle

@article{57a214e5efd84e1b89cf3c33cd50c807,
title = "Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: Possible relevance to the effects of mGlu5R blockade in Parkinson's disease",
abstract = "This study was designed to test whether chronic treatment with the metabotropic glutamate receptor 5 (mGlu5R) antagonist MPEP showed antiparkinsonian effects in rats unilaterally lesioned with 6-hydroxydopamine (6-OHDA) (a {"}classic{"} model of Parkinson's disease, PD), and to evaluate whether chronic MPEP influenced the functional properties and/or the expression of striatal mGlu5Rs. Wistar rats were lesioned with 6-OHDA and then treated with MPEP (3 mg/kg/day, i.p.) or its vehicle over 2 weeks. Chronic MPEP did not induce measurable antiparkinsonian effects, since no differences were found between MPEP- and vehicle-treated animals in the pattern of L-DOPA-induced contralateral rotations. In corticostriatal slices taken from animals chronically treated with MPEP, the functional effects of the mGlu5R agonist CHPG were significantly reduced in the lesioned vs. the intact side, while no changes were found in slices taken from vehicle-treated rats. The binding of [3H]MPEP to striatal membranes showed that neither the maximal number of binding sites (Bmax) nor the dissociation constant (Kd) were changed by the lesion and/or by chronic MPEP. While chronic MPEP did not potentiate L-DOPA-induced turning in a classical model of PD, its ability to reduce mGlu5R-associated signal could help to explain the neuroprotective/ antiparkinsonian effects observed in other models of PD.",
keywords = "Binding, Electrophysiology, L-DOPA, mGlu5 receptors, Parkinson's disease, Striatum",
author = "Domenici, {Maria Rosaria} and Potenza, {Rosa Luisa} and Alberto Martire and Roberto Coccurello and Antonella P{\`e}zzola and Rosaria Reggio and Tebano, {Maria Teresa} and Patrizia Popoli",
year = "2005",
month = "6",
day = "1",
doi = "10.1002/jnr.20489",
language = "English",
volume = "80",
pages = "646--654",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats

T2 - Possible relevance to the effects of mGlu5R blockade in Parkinson's disease

AU - Domenici, Maria Rosaria

AU - Potenza, Rosa Luisa

AU - Martire, Alberto

AU - Coccurello, Roberto

AU - Pèzzola, Antonella

AU - Reggio, Rosaria

AU - Tebano, Maria Teresa

AU - Popoli, Patrizia

PY - 2005/6/1

Y1 - 2005/6/1

N2 - This study was designed to test whether chronic treatment with the metabotropic glutamate receptor 5 (mGlu5R) antagonist MPEP showed antiparkinsonian effects in rats unilaterally lesioned with 6-hydroxydopamine (6-OHDA) (a "classic" model of Parkinson's disease, PD), and to evaluate whether chronic MPEP influenced the functional properties and/or the expression of striatal mGlu5Rs. Wistar rats were lesioned with 6-OHDA and then treated with MPEP (3 mg/kg/day, i.p.) or its vehicle over 2 weeks. Chronic MPEP did not induce measurable antiparkinsonian effects, since no differences were found between MPEP- and vehicle-treated animals in the pattern of L-DOPA-induced contralateral rotations. In corticostriatal slices taken from animals chronically treated with MPEP, the functional effects of the mGlu5R agonist CHPG were significantly reduced in the lesioned vs. the intact side, while no changes were found in slices taken from vehicle-treated rats. The binding of [3H]MPEP to striatal membranes showed that neither the maximal number of binding sites (Bmax) nor the dissociation constant (Kd) were changed by the lesion and/or by chronic MPEP. While chronic MPEP did not potentiate L-DOPA-induced turning in a classical model of PD, its ability to reduce mGlu5R-associated signal could help to explain the neuroprotective/ antiparkinsonian effects observed in other models of PD.

AB - This study was designed to test whether chronic treatment with the metabotropic glutamate receptor 5 (mGlu5R) antagonist MPEP showed antiparkinsonian effects in rats unilaterally lesioned with 6-hydroxydopamine (6-OHDA) (a "classic" model of Parkinson's disease, PD), and to evaluate whether chronic MPEP influenced the functional properties and/or the expression of striatal mGlu5Rs. Wistar rats were lesioned with 6-OHDA and then treated with MPEP (3 mg/kg/day, i.p.) or its vehicle over 2 weeks. Chronic MPEP did not induce measurable antiparkinsonian effects, since no differences were found between MPEP- and vehicle-treated animals in the pattern of L-DOPA-induced contralateral rotations. In corticostriatal slices taken from animals chronically treated with MPEP, the functional effects of the mGlu5R agonist CHPG were significantly reduced in the lesioned vs. the intact side, while no changes were found in slices taken from vehicle-treated rats. The binding of [3H]MPEP to striatal membranes showed that neither the maximal number of binding sites (Bmax) nor the dissociation constant (Kd) were changed by the lesion and/or by chronic MPEP. While chronic MPEP did not potentiate L-DOPA-induced turning in a classical model of PD, its ability to reduce mGlu5R-associated signal could help to explain the neuroprotective/ antiparkinsonian effects observed in other models of PD.

KW - Binding

KW - Electrophysiology

KW - L-DOPA

KW - mGlu5 receptors

KW - Parkinson's disease

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=21244460356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244460356&partnerID=8YFLogxK

U2 - 10.1002/jnr.20489

DO - 10.1002/jnr.20489

M3 - Article

C2 - 15880742

AN - SCOPUS:21244460356

VL - 80

SP - 646

EP - 654

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 5

ER -